Patents
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
01/2009
01/21/2009CN100453116C Process for preparing compound aminophylline tablet
01/21/2009CN100453106C Chinese medicine compound preparation for treating laryngopharyngitis and tonsillitis and its preparing method
01/21/2009CN100453097C Composite medicine for coronary heart disease and angina pectoris and its preparation
01/21/2009CN100453092C Use of a lupeol-rich extract to make a pharmaceutical or cosmetic composition for treating or preventing degeneration of dermal, cartilage and/or gingival connective tissue
01/21/2009CN100453086C Gel for removing ocular by ice pearl and its preparation
01/21/2009CN100453083C Dextran iron dispersing agent and its prepn. method
01/21/2009CN100453082C Compound terbinafine and root of large flowered skullcap cream and its preparing method
01/21/2009CN100453081C Pyridylsulfonamido pyrimidines for treating diabetic nephropathy
01/21/2009CN100453080C Lindera root alkaloid, its preparation method and application in medicine preparation
01/21/2009CN100453079C Water-soluble liquid internal medicine
01/21/2009CN100453078C Method for treating primary insomnia
01/21/2009CN100453077C Injectable micelle prepn containing garcinolic acid and its prepn process
01/21/2009CN100453076C Application of phenhexyl isothiocyanate in preparation of medicament for treating leukemia
01/21/2009CN100453075C Novel association consisting of an anti-atherothrombotic agent and of a platelet antiaggregating agent
01/21/2009CN100453074C Sustained release drug delivery device
01/21/2009CN100453071C Oral resveratrol multi-phase liposome and preparation method thereof
01/21/2009CN100453069C Biphenyl diester emulsion and its preparing method
01/21/2009CN100453068C Injection containing caderfloxacin lactate
01/21/2009CN100453067C Preparation of injectable suspensions having improved injectabity
01/21/2009CN100453066C Drug delivery system using subconjunctival depot
01/21/2009CN100452984C Aimal growth regulating composition and its prepn and use
01/20/2009US7479573 Cationic lipids capable of facilitating transport of biologically active agents or substances into cells; lipid aggregate macromolecular complex interacts with cells making the polyanionic macromolecule available for absorption and uptake by the cell
01/20/2009US7479572 Solvent system comprising isopropyl alcohol, water and toluene; recrystallization production of pure, thermodynamically stable form; long lasting bronchodilating effect
01/20/2009US7479571 Generation of combinatorial synthetic libraries and screening for novel proadhesins and nonadhesins
01/20/2009US7479564 e.g. 6-ethyl-5-(4-{2-[({[(4-methylphenyl)sulfonyl]amino}carbonyl)amino]ethyl}phenyl)-5H-[1,3]dioxolo[4,5-f]benzimidazole; prostaglandin E2 receptor antagonists; arthritis, hyperalgesia, uterine contraction, digestive peristalsis, awakeness, blood pressure, platelet function, bone metabolism, angiogenesis
01/20/2009US7479563 Method of producing polymorphic crystals of donepezil hydrochloride
01/20/2009US7479559 3-[-2-(Piperazin-1-yl)benzyl]pyrrolidin-2-one derivatives; antidepressants, anxiolytic agents; obsessive compulsive disorder, psychological disorders, phobias; 5-HT1 agonist or antagonists; side effect reduction, in particular cardiac QTc prolongation; hydrogenation
01/20/2009US7479541 and fusion proteins with green fluorescent protein, used for modulating cell differentiation and apoptosis, including cell formation of tissues
01/20/2009US7479536 Chiral, charged peptide nucleic acid oligomers from cyclic monomers
01/20/2009US7479535 Star polymer such as of a polylactone based on a central phosphorus atom derived from phosphorus oxychloride (POCl3) or ethyl dichlorophosphate; biodegradable and/or biocompatible; sustained release drug delivery; reverse thermal gelation
01/20/2009US7479508 Nimesulide containing topical pharmaceutical compositions
01/20/2009US7479507 Anti-inflammatory substituted phenols and elastomeric compositions for oral delivery of drugs
01/20/2009US7479506 administering a formulation comprising 2-oxo-1-pyrrolidineacetamide (piracetam) as an active ingredient and a pharmaceutically acceptable carrier for treating aphasia stage when no expectation of improvement in symptoms after at least 3 years of language rehabilitation
01/20/2009US7479505 Administering taurolidine, taurultam, or a biologically active derivative to mammal to directly contact tumor cell at dosage sufficient to induce cell death by apoptosis; side effect reduction
01/20/2009US7479504 Edg receptor agonists
01/20/2009US7479503 Such as multiple sclerosis; also inactivating HIV virus via extracorporeal treatment of blood; use of a green porphyrin or porfimer sodium
01/20/2009US7479502 2-(2-hydroxybiphenyl-3-yl)-1H-benzoimidazole-5-carboxamidine derivatives as factor VIIA inhibitors
01/20/2009US7479501 Heteroaryl-cyclic acetals
01/20/2009US7479500 Antidepressant piperidine derivatives of heterocyclefused benzodioxans
01/20/2009US7479499 Methods of using thalidomide in combination with irinotecan
01/20/2009US7479498 Treatments for viral infections
01/20/2009US7479497 e.g. 8-hydroxy-2-[2-[3,4-dihydroxy-5-methoxyphenyl)ethenyl]]-7-quinoline carboxylic acid; HIV integrase inhibitors; AIDS, retroviral pathologies
01/20/2009US7479496 Substituted spiro azabicyclics as modulators of chemokine receptor activity
01/20/2009US7479495 N-heterocyclic inhibitors of TNF-α expression
01/20/2009US7479494 3-monosubstituted tropane derivatives as nociceptin receptor ligands
01/20/2009US7479493 e.g. [4-(3,4-Dichloro-phenoxy)-3-methylaminomethyl-phenyl]-(4-isopropyl-piperazin-1-yl)-methanone; histamine H3 receptor and/or serotonin transporter modulator; antidepressant; cognitive disorders, sleep disorders, psychiatric disorders, drug abuse, sexual dysfunction
01/20/2009US7479492 Use combined 5-HT1A agonists and selective serotonin reuptake inhibitors
01/20/2009US7479491 Azanthranylalkyl and -cycloalkyl amides and their use as VEGF receptor inhibitors
01/20/2009US7479490 pellets comprising resazurin, anhydrous sodium sulfate, 1-hydroxyethylidene biphosphonate, tetrasodium salt and magnesium stearate
01/20/2009US7479489 Heterocyclic antiviral compounds
01/20/2009US7479488 Selected CGRP—antagonists, process for preparing them and their use as pharmaceutical compositions
01/20/2009US7479486 Sulphur analogues of 21-hydroxy-6,19-oxidoprogesterone (21OH-6OP) for treating excess of glucocorticoids
01/20/2009US7479485 Method of treating arrhythmias
01/20/2009US7479483 Tumor-targeted drug delivery systems and uses thereof
01/20/2009US7479476 Antimicrobial compositions comprising polymeric stabilizers
01/20/2009US7479376 Using caudal-1 gene (CDX-1) as diagnostic indicator of stomach or esophageal cancer; immunodiagnostics
01/20/2009US7479286 Microbiocides fatty acid mixed with feed
01/20/2009US7479279 Use of cytokines of the TGF-β superfamily for the treatment, inhibition and/or diagnosis of skin related disorders
01/20/2009US7479276 Antibody fragment-targeted immunoliposomes for systemic gene delivery
01/20/2009CA2586146C Fluorocarbon aerosol medicaments
01/20/2009CA2528493C Medicinal composition containing triazole compound
01/20/2009CA2521030C 4-(2-phenyloxyphenyl)-piperidine or -1,2,3,6-tetrahydropyridine derivatives as serotonin reuptake inhibitors
01/20/2009CA2502856C Intermediates for retroviral protease inhibiting compounds
01/20/2009CA2499698C Proline derivatives having affinity for the calcium channel alpha-2-delta subunit
01/20/2009CA2477839C Nitrogen containing heterocyclic compounds and medicines containing the same
01/20/2009CA2468916C A stable oxaliplatin solution formulation
01/20/2009CA2465871C Heteroaryl derivatives as superior ligands for nociceptin receptor orl-1
01/20/2009CA2465738C Unsaturated 1-amino-alkylcyclohexane nmda, 5ht3 and neuronal nicotinic receptor antagonists
01/20/2009CA2445519C Method for manufacturing a low dose pharmaceutical composition
01/20/2009CA2444116C Pharmaceutical dosage form of amorphous nelfinavir mesylate
01/20/2009CA2432172C An in vivo method for producing female offsprings in mammals
01/20/2009CA2423252C Photosensitisers
01/20/2009CA2423020C Use of antiprogestins for the induction of apoptosis in a cell
01/20/2009CA2415438C .alpha. crystalline form of perindopril tert-butylamine salt
01/20/2009CA2401048C 2-oxo-1-pyrrolidine derivatives, process for preparing them and their uses
01/20/2009CA2396678C Peptide derivatives and their pharmaceutically acceptable salts, processes for preparation of both, and use thereof
01/20/2009CA2393518C Amycomycin, a process for its production and its use as a pharmaceutical
01/20/2009CA2391239C Benzopyran derivative and antiallergic agent
01/20/2009CA2383916C Dispersion formulations containing lipase inhibitors
01/20/2009CA2383241C Formulations of paclitaxel entrapped into nanoparticles of polymeric micelles
01/20/2009CA2376676C Respiratory syncytial virus replication inhibitors
01/20/2009CA2373484C Use of 1,4-benzothiazepine derivatives as drugs for overcoming resistance to anticancer drugs
01/20/2009CA2372836C Substituted pyrrolidines as cell adhesion inhibitors
01/20/2009CA2366268C Pharmaceutical compositions for cns and other disorders
01/20/2009CA2365240C Regulation of phospholipase d activity
01/20/2009CA2364944C C16 unsaturated fp-selective prostaglandins analogs
01/20/2009CA2355644C Controlled/modified release oral methylphenidate formulations
01/20/2009CA2352762C Oral transmucosal delivery
01/20/2009CA2352389C An oral formulation for gastrointestinal drug delivery
01/20/2009CA2348759C Gel compositions
01/20/2009CA2344411C 2-arylalkylthio -imidazoles, 2-arylalkenyl -thio -imidazoles and 2-arylalkinyl -thio -imidazoles as anti -inflammatory substances and substances inhibiting the release of cytokine
01/20/2009CA2339961C Isoquinoline derivatives with angiogenesis inhibiting activity
01/20/2009CA2339193C Pharmaceutical compositions comprising ibuprofen and domperidone
01/20/2009CA2338794C New oral formulation for 5-ht4 agonists or antagonists
01/20/2009CA2337770C Amide derivatives which are useful as cytokine inhibitors
01/20/2009CA2327495C Form vi 5,6-dichloro-2-(isopropylamino)-1-(.beta.-l-ribofuranosyl)-1h-benzimidazole
01/20/2009CA2325633C Steroidal sapogenins and their derivatives for treating alzheimer's disease
01/20/2009CA2322204C 5-aminoindeno(1,2-c)pyrazol-4-ones as anti-cancer and anti-proliferative agents
01/20/2009CA2317008C Water soluble prodrugs of tertiary amine containing drugs and methods of making thereof
01/20/2009CA2312795C The use of phospholipid complexes of extracts of vitis vinifera as anti-atherosclerotic agents